Schrodinger, Inc. ( (SDGR) ) has released its Q4 earnings. Here is a breakdown of the information Schrodinger, Inc. presented to its investors.
Schrödinger, Inc. is a company that specializes in molecular discovery through its computational platform, primarily serving the biotechnology and pharmaceutical sectors. The company recently reported strong financial results for the fourth quarter and full year of 2024, with a notable increase in software revenue and expanded collaborations. Key highlights from the report include a 13.3% increase in software revenue to $180.4 million for 2024, driven by large contract renewals and new agreements. The company also expanded its research collaboration with Eli Lilly and Company and is on track to report initial Phase 1 data from three proprietary programs in 2025. Despite a net loss of $187.1 million for the year, Schrödinger remains optimistic about its financial outlook for 2025, expecting software revenue growth of 10% to 15% and drug discovery revenue between $45 million and $50 million. The company’s management is confident in its strategic positioning and plans to continue advancing its platform and collaborations in the coming year.